Patenting genes

British Medical Journal

Volumn 329, Issue 7479, 2004, Pages 1358-1360

  Matthijs, Gert ^a,b  

^a Laboratory for Molecular Diagnosis   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENETIC ANALYSIS; GENETIC ENGINEERING; GENETIC PROCEDURES; HUMAN; LABORATORY TEST; ONCOGENE; PATENT; PRIORITY JOURNAL;

EID: 10644221913     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7479.1358     Document Type: Editorial

References (9)

1. Matthijs G, Halley D. European-wide opposition against the breast cancer gene patents. Eur J Hum Genet 2002:10:783-5
2. European Patent Office. "Myriad/breast cancer" patent revoked after public hearing. Press release, 2004. www.european-patent-office.org/ news/pressrel/2004_05_18_e.htm (accessed 18 May, 2004)
3. Cancer Research UK. Charities to make breast cancer (BRCA2) gene freely available across Europe. Press release, 2004. www.cancerresearchuk.org/ news/pressreleases/breastcancergene_11feb04?version = 1 (accessed 11 Feb 2004).
4. Directive 98/44/EC of the European Parliament and of the Council, 6 July 1998.
5. Nuffield Council on Bioethics. The ethics of patenting DNA, a discussion paper. www.nuffieldbioethics.org/publications/pp_0000000014.asp (accessed 3 Jun 2004).
6. American College of Medical Genetics. Position statement on gene patents and accessibility of gene testing. http://genetics.faseb.org/ genetics/acmg/pol-34.htm (accessed 3 Jun 2004).
7. Sevilla C, Moatti JP, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 2002;10:599-606.
8. Merz JF, Kriss AG, Leonard DG, Cho MK. Diagnostic testing fails the test. Nature 2002;415:577-9.
9. European Patent Convention. European patent convention. http:// www3.european-patent-office.org/legal/epc/index.html (accessed 3 Jun 2004).